RALLYBIO CORPORATION Amortization of Debt Discount (Premium)
RALLYBIO CORPORATION (RLYB) reported Amortization of Debt Discount (Premium) of -$56.00 thousand for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-26
- RALLYBIO CORPORATION amortization of debt discount (premium) for the quarter ending 2026-06-30 was -$5.00K.
- RALLYBIO CORPORATION amortization of debt discount (premium) for the quarter ending 2026-03-31 was -$51.00K.
- RALLYBIO CORPORATION amortization of debt discount (premium) for the quarter ending 2025-12-31 was -$97.00K.
- RALLYBIO CORPORATION amortization of debt discount (premium) for the quarter ending 2025-09-30 was -$113.00K.
- RALLYBIO CORPORATION amortization of debt discount (premium) for fiscal 2023 was -$3.09M.
- RALLYBIO CORPORATION amortization of debt discount (premium) for fiscal 2022 was -$435.00K.
- RALLYBIO CORPORATION amortization of debt discount (premium) for fiscal 2021 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$56.00K S-4/A · filed 2026-08-26 | -$153.00K derived: sum of 3 quarters · filed 2026-08-26 | -$266.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | -$51.00K S-4 · filed 2026-07-15 | -$148.00K derived: sum of 2 quarters · filed 2026-08-26 | -$261.00K derived: sum of 3 quarters · filed 2026-08-26 | -$414.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -$97.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$210.00K derived: sum of 2 quarters · filed 2026-08-26 | -$363.00K derived: sum of 3 quarters · filed 2026-08-26 | -$573.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | -$113.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | -$266.00K derived: sum of 2 quarters · filed 2026-08-26 | -$476.00K 10-Q · filed 2025-11-06 | -$792.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | -$153.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$363.00K S-4/A · filed 2026-08-26 | -$679.00K derived: sum of 3 quarters · filed 2026-08-26 | -$1.02M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | -$210.00K S-4 · filed 2026-07-15 | -$526.00K derived: sum of 2 quarters · filed 2026-08-26 | -$867.00K derived: sum of 3 quarters · filed 2026-08-26 | -$1.28M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$316.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$657.00K derived: sum of 2 quarters · filed 2026-08-26 | -$1.07M derived: sum of 3 quarters · filed 2026-08-26 | -$1.61M S-4/A · filed 2026-08-26 |
| 2024-09-30 | -$341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$757.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.30M 10-Q · filed 2025-11-06 | -$1.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$416.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$955.00K 10-Q · filed 2025-08-07 | -$1.61M derived: sum of 3 quarters · filed 2025-08-07 | -$2.31M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$539.00K 10-Q · filed 2025-05-08 | -$1.20M derived: sum of 2 quarters · filed 2025-05-08 | -$1.90M derived: sum of 3 quarters · filed 2025-05-08 | -$2.73M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$657.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$1.36M derived: sum of 2 quarters · filed 2025-03-13 | -$2.19M derived: sum of 3 quarters · filed 2025-03-13 | -$3.09M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$703.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.54M derived: sum of 2 quarters · filed 2024-11-07 | -$2.43M 10-Q · filed 2024-11-07 | -$2.89M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$834.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.73M 10-Q · filed 2024-08-08 | -$2.19M derived: sum of 3 quarters · filed 2024-08-08 | -$2.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$895.00K 10-Q · filed 2024-05-09 | -$1.36M derived: sum of 2 quarters · filed 2024-05-09 | -$1.44M derived: sum of 3 quarters · filed 2024-05-09 | -$1.37M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$544.00K derived: sum of 2 quarters · filed 2024-03-12 | -$471.00K derived: sum of 3 quarters · filed 2024-03-12 | -$435.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | -$82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$9.00K derived: sum of 2 quarters · filed 2023-11-09 | $27.00K 10-Q · filed 2023-11-09 | $27.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $109.00K 10-Q · filed 2023-08-08 | $109.00K derived: sum of 3 quarters · filed 2023-08-08 | $109.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $36.00K 10-Q · filed 2023-05-09 | $36.00K derived: sum of 2 quarters · filed 2023-05-09 | $36.00K derived: sum of 3 quarters · filed 2023-05-09 | $36.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |